KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Accounts Payables (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Accounts Payables data on record, last reported at $122.1 million in Q4 2025.

  • For Q4 2025, Accounts Payables rose 56.75% year-over-year to $122.1 million; the TTM value through Dec 2025 reached $122.1 million, up 56.75%, while the annual FY2025 figure was $122.1 million, 56.75% up from the prior year.
  • Accounts Payables reached $122.1 million in Q4 2025 per JAZZ's latest filing, down from $152.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $152.2 million in Q3 2025 and bottomed at $63.8 million in Q3 2021.
  • Average Accounts Payables over 5 years is $94.2 million, with a median of $93.3 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: skyrocketed 272.23% in 2021, then tumbled 35.45% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $100.3 million in 2021, then fell by 9.51% to $90.8 million in 2022, then rose by 13.21% to $102.8 million in 2023, then dropped by 24.22% to $77.9 million in 2024, then soared by 56.75% to $122.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $122.1 million in Q4 2025, $152.2 million in Q3 2025, and $89.4 million in Q2 2025.